Introduction
Gene therapy is a relatively new and evolving paradigm for treating human illness. At its inception, it was considered that gene therapy would treat genetic disorders, such as inborn errors of metabolism, by expressing a therapeutic gene for augmentation or replacement of a defective homologous gene, in order to correct the disease phenotype. The field of gene therapy now also includes the treatment of chronic infections and cancer by expression of antigenic proteins for the purpose of inducing immune responses that will clear the infection or destroy the neoplastic cells. However, for the purpose of this article, strategies where immune responses are desired will be called DNA-based immunization and the term gene therapy will be restricted to those situations where long-term stable expression of the therapeutic gene product is desired.
With gene therapy, the therapeutic gene product may be seen as foreign by the immune system and resulting immune responses can destroy transfected cells or neutralize the therapeutic gene product. This is particularly true in cases where the genetic abnormality results in a complete absence of the normal structural or functional protein, but it can also occur in cases where a truncated or otherwise abnormal gene product is missing an epitope normally found in the complete protein. transfer of a dystrophin mini-gene into dystrophindeficient mice (mdx mice) is capable of correcting morphological and physiological abnormalities in the muscle fibers. However, dystrophin expression was found to be transient unless immunosuppression was used. 1 Similar observations have been made in other disease models such as cystic fibrosis (CF) 2 and hemophilia A. 3 It is clear that loss of the therapeutic gene expression and transfected cells is immune mediated, since such losses do not occur in immunocompromised animals. [4] [5] [6] The knowledge gathered from the field of DNA-based immunization may provide important insight for the field of gene therapy. It was initially thought that the efficacy of DNA vaccines was by virtue of in vivo synthesis of antigen in transfected cells, for example muscle cells after intramuscular (i.m.) injection of plasmid DNA. However, it was subsequently shown that only professional antigen-presenting cells (APC) could actually prime immune responses with DNA vaccines. [7] [8] [9] [10] While direct transfection of APC is not absolutely essential, 11 it is probable that some APC are transfected and antigen expression in these APC primes MHC class I and II responses. This may account for the strong immune responses induced by DNA vaccines, especially considering the extremely small quantities of antigen expressed from typical doses of plasmid DNA. Furthermore, most DNA-based immunization strategies use strong viral promoters to ensure high levels of expression. These promoters are ubiquitously expressed and will drive antigen expression in a wide range of cell types, including APC. Therefore by using strategies that avoid gene expression in APC, it may be possible to abrogate unwanted immune responses against a desired gene. We have evaluated this possibility using a modification of our well-established DNA vaccine model whereby expression of HBsAg under the control of a ubiquitously expressed promoter induces strong antibodies against HBsAg (antiHBs) and cytotoxic T lymphocytes (CTL) responses. [12] [13] [14] [15] [16] Herein we show that expression of the same highly antigenic HBsAg protein does not elicit, or even prime, any immune responses when expressed under the control of muscle-specific creatine kinase (MCK) promoters that express poorly or not at all in cells of the lymphocytic lineage.
Results

Tissue specificity of CMV and MCK promoters in vitro
Luciferase reporter expressed under the control of CMV or MCK promoters in the mouse myoblast/myotube (muscle, C2C12) and mouse monocyte/macrophage (RAW264.7) cell lines were used to assess the tissue specificity of these promoters.
When tested in vitro, the CMV promoter drove strong expression of luciferase in both mouse myoblast/ myotube (muscle, C2C12) and mouse monocyte/ macrophage (RAW264.7) cell lines (assayed 2 days after transfection). A given dose of DNA gave approximately 100-fold higher expression in the C2C12 than RAW264.7 cells (Figure 1 ).
In contrast, the pMCK-luc vector gave high luciferase activity in C2C12 cells, but no detectable activity in RAW264.7 cells, indicating a strong muscle tissue-specificity of the MCK promoter/intron region. Luciferase reporter gene expression in muscle cells with 5 g pMCK-luc was nearly as high as with 1 g pCMV-luc (Figure 1 ), indicating very strong activity since CMV is one of the strongest promoters known. However, the reduction in luciferase expression seen with pMCK-luc Gene Therapy might also be attributed to the decrease in transfection efficiency due to its large size. In order to rectify this, the intron following the MCK promoter region was deleted from the expression vectors (⌬MCK).
The p⌬MCK-luc vector gave approximately five-fold higher luciferase levels than pMCK-luc in the muscle cell line, but lost some of its muscle specificity as there were also detectable levels of luciferase in the macrophage cell line.
Activity of CMV and MCK promoters in vivo
Each of pCMV-luc, pMCK-luc and p⌬MCK-luc vectors gave high levels of luciferase reporter gene activity in muscle in vivo (Figure 2a ). Luciferase levels in TA muscles removed 3 days after injection were significantly higher with 10 g of pCMV-luc than with 10 g of either pMCK-luc or p⌬MCK-luc (P Ͻ 0.001). However, there was no significant difference between levels with 10 g of pCMV-luc and 100 g of p⌬MCK-luc (P = 0.1742) or 
-S (left panel), pMCK-S (middle panel) or p⌬MCK-S (right panel). Each bar represents the group mean (n = 5-10) for titers of anti-HBs (total IgG) at 4 weeks after injection, as determined in triplicate by end-point dilution ELISA assay. End-point titers were defined as the highest plasma dilution that resulted in an absorbance value (OD 450) two times greater than that of control non-immune plasma with a cut-off value of 0.05. The numbers above the individual bars indicate the number of animals seroconverted/total number of animals injected.
5 g of pCMV-luc and 10 g of pMCK-luc (P = 0.8564). Notably, luciferase levels in muscles injected with 5 g of pCMV-luc were significantly lower than in the muscles injected with either 10 or 100 g of p⌬MCK-luc (P = 0.0335 and P = 0.0013).
Expression of HBsAg by CMV and MCK promoters in vitro
Before use in vivo, all of the plasmid constructs, pCMV * -S, pMCK-S and p⌬MCK-S, were tested and confirmed for expression of HBsAg in C2C12 cells in vitro ( Figure 3 ). The plasmid pCMV * -S is identical to the plasmid reported earlier as pMAS-S. However, we use the nomenclature pCMV * -S in this manuscript to emphasize the use of CMV promoter in this vector to drive expression of HBsAg.
Immune responses against HBsAg in mice
Humoral response: As shown previously, 15 animals injected with the plasmid expressing HBsAg under the control of the CMV promoter (pCMV-S) showed 100% seroconversion (ELISA titers >100) by 2 weeks after injection with the 100-g dose and by 4 weeks with the 10-g dose. In contrast, seroconversion was not observed by 4 weeks after injection in animals injected with 10 or 100 g of the vectors expressing HBsAg under the control of the muscle creatine kinase promoter, both with (pMCK-S) and without the first intron (p⌬MCK-S) (Figure 2b ). Seroconversion was only ever detected in one of six animals injected with 10 g pMCK-S (end point titer of 200 at 8 weeks). Thus, only one of 32 animals injected with
Figure 3 Expression of HBsAg in C2C12 (murine myoblast cells) transfected with pCMV (upper left panel), pCMV * -S (upper right panel), pMCK-S (lower left panel) or p⌬MCK-S (lower right panel). C2C12 cells were transfected with 10 g of DNA. Expression of HBsAg was detected by immunoassay using mouse anti-HBs polyclonal antibody and fluorescein-labeled sheep anti-mouse IgG (F[ab'] 2 fragment). The cells were examined by confocal microscopy for HBsAg expression, which is evident as green fluorescence.
10 or 100 g of either pMCK-S (n = 11) or p⌬MCK-S (n = 20) seroconverted. When 16 of the non-responding animals were 'challenged' with 1 g of recombinant HBsAg protein at 8 weeks, all mice exhibited a typical primary response, similar to that seen in naive mice receiving HBsAg for the first time. This primary response, which was characterized by no seroconversion by 7 days and only weak responses (mean titers Ͻ200) by 14 days, indicated that HBsAg-specific responses had not even been primed by the plasmids driven by the muscle-specific promoters (Figure 4) . In contrast, mice that had been primed by injection of pCMV-S at 7 days of age in the presence of maternal anti-HBs antibody, but which had no detectable anti-HBs after the maternal antibodies had waned (by 12 weeks), showed a strong anamnestic response upon subsequent 'challenge' with HBsAg. In this case, seroconversion was evident by 3 days and high titers (>1000) were detectable by 7 days (Figure 4 ).
Cell-mediated response:
Splenocytes recovered from mice 4 weeks after i.m. injection with 5, 10 and 100 g of pCMV * -S showed HBsAg-specific lysis of 72%, 71% and 45%, respectively, at an E:T ratio of 50:1. In contrast, animals injected with 100 g of either pMCK-S or p⌬MCK-S did not show levels of CTL activity above noninjected controls (Ͻ20% lysis at an E:T ratio of 50:1) ( Figure 5 ).
Discussion
We have evaluated whether immune responses against a foreign protein expressed after i.m. injection of plasmid DNA would be abrogated by use of a tissue-specific promoter that would not be active in APC. Herein we show that expression of HBsAg, a highly antigenic protein, under the control of the human muscle-specific promoter (MCK) with or without the intron region, does not induce humoral or cell-mediated immune responses against HBsAg in mice. Furthermore, it appears that antigen-specific immune responses were not even primed with these vectors, since animals do not show anamnestic antibody responses upon subsequent challenge with recombinant HBsAg. In contrast, all animals injected with the pCMV * -S vector, where the ubiquitous CMV promoter drives expression of HBsAg, developed strong antibody and CTL against HBsAg. This was true even at doses where less gene product would have been produced from the CMV than the MCK plasmids.
There have been several studies on DNA vaccines reporting that only professional APC can prime immune responses with DNA-based immunization. [7] [8] [9] [10] Other studies have shown increased efficacy of DNA vaccines with ex vivo transfection of dendritic cells (DC). 17, 18 The finding that transfected muscle cells cannot prime immune responses was not unexpected since they do not normally express class II MHC molecules or the co-stimulatory molecules necessary to activate T cells. 19 However, muscle cells are efficiently transfected by plasmid DNA, 20, 21 and thus they may help boost immune responses once they are primed. Even this does not appear to be necessary since immediate removal of a muscle immediately after i.m. injection of a DNA vaccine does not diminish immune responses. 22 These results suggest that some of the plasmid DNA injected i.m. exits the muscle immediately. This might be via the lymphatic system, and indeed it has been shown that after i.m. injection, some cells in the draining lymph nodes are transfected. 17, 23 A study by Loirat et al 24 showed that immunizing mice with a DNA vaccine expressing HBsAg under the control of a musclespecific promoter derived from human desmin gene Gene Therapy resulted in both humoral and CTL immune responses against HBsAg. However, the authors in this study have not confirmed the muscle specificity of this promoter and thus it is possible that the HBsAg is also expressed in APC transfected with the DNA, which are then involved in the induction of immune responses. Thus, although the absolute necessity for transfection of APC is still controversial, it is likely that expression of a foreign protein from a DNA vaccine within normal host cells that are not APC will not induce immune responses. Indeed, in the present study we show that expression of antigen in mature muscle fibers does not induce immune responses.
It is possible that the failure to induce immune responses in the present study is simply due to expression of an inadequate quantity of antigen with the MCK promoters compared with the stronger CMV promoter. However, this is unlikely to be the case since i.m. injection of 100 g of the p⌬MCK-luc gave the same level of luciferase activity in muscle as 10 g of pCMV-luc, yet there were no immune responses with 100 g of p⌬MCK-S and very strong responses with 10 g of pCMV * -S. Furthermore, we have been able to detect both antibody and CTL responses in mice injected with 5 g pCMV * -S, even though 5 g of pCMV-luc gave a considerably lower level of luciferase expression than 10 or 100 g of p⌬MCK-luc. We have previously shown a strong correlation between the level of luciferase expression by pCMV-luc (which indicates the efficiency of muscle cell transfection and promoter activity) and anti-HBs humoral immune responses induced by pCMV-S. 25 As mentioned earlier, an important problem for gene therapy applications today is unwanted immune responses against the therapeutic gene product. We have previously shown immune-mediated destruction of virtually all HBsAg-expressing muscle fibers following i.m. injection of HBV DNA vaccines, and this occurs largely between 10 and 20 days after gene transfer. 15 Thus the results of this study may have important clinical implications for the gene therapy field. However, it will be necessary to identify tissue-specific promoters that allow high levels of expression in the cells of choice.
Materials and methods
Plasmid construction
Starting plasmids: A 2.7-kb DNA fragment containing the human muscle creatine kinase (MCK) promoter was provided by Dr Richard J Bartlett (University of Miami). This fragment contains a 5' BamHI site and 3' HindIII site before the splice donor site for the first intron. Plasmid p31C, which contains the MCK first intron subcloned into the original TA cloning vector pCRTM2.1 (Invitrogen, Carlsbad, CA, USA) was also provided by Dr Bartlett. The start codon within the MCK first intron on pC31 was mutated to the unique restriction enzyme site SalI. The cloning vector pUK21, which contains a kanamycin resistance gene and multiple cloning sites, was provided by Dr Martin Schleef (Qiagen, Hilden, Germany). The luciferase reporter vector pGL2-Basic was purchased from Promega (Madison, WI, USA). The plasmid pMAS-S (GeneBank accession number AFO53407), expresses the small hepatitis B surface antigen (HBsAg, ay subtype) under the control of the human cytomegalovirus (CMV) major intermediate-early promoter/enhancer region. 26 In order to emphasize the presence of the CMV promoter, pMAS-S will be referred to as pCMV * -S throughout this article. E. coli strain DH5␣ was used as the bacterial host.
Expression vectors with the MCK promoter/intron region:
The 2.7 kb DNA fragment containing the MCK promoter was cloned into pUK21 using the BamHI and HindIII sites, creating pUK21-MCK. p31C was digested with KpnI, blunt-ended, and then digested with SphI to excise the MCK first intron. pUK21-MCK was digested with XhoI, blunt-ended, and then digested with SphI for insertion of the MCK intron. Insertion of the intron fragment into the pUK21-MCK created the plasmid pUK21-MCKIN, which contains the 5.9-kb full-length MCK promoter and the first intron. The 5.9 kb promoter/intron region was then excised from pUK21-MCKIN using EcoRV and SalI sites, blunt-ended, and cloned into pGL2-Basic using blunt-ended HindIII and SacI sites. The resulting plasmid, pMCK-luc, expresses luciferase driven by the full-length MCK promoter. The CMV promoter was removed from pCMV * -S using HpaI and EcoRI sites, blunt-ended, and then replaced with the 5.9-kb bluntended MCK promoter/intron region. The resulting plasmid, pMCK-S, expresses the HBsAg under the control of the MCK promoter and first intron.
Expression vectors with the MCK promoter:
The 2.7-kb MCK promoter was excised from pUK21-MCK with EcoRV and HindIII, and then cloned into pGL2-Basic using SmaI and HindIII sites. The resulting plasmid, p⌬MCK-luc, expresses luciferase driven by the MCK promoter. The 2.7-kb MCK promoter fragment containing terminal EcoRV and HindIII sites was blunt-ended, then used to replace the CMV promoter of pCMV * -S, creating p⌬MCK-S, which expresses HBsAg under the control of the MCK promoter.
DNA production: All plasmid DNA was produced by growing transformed E. coli cells (DH5-␣) in LB media and then purified on Qiagen DNA purification columns (Qiagen). Recovered DNA was redissolved in 0.15 m NaCl and stored at or below Ϫ20°C.
In vitro assays of gene expression
Luciferase expression: C2C12 (murine myoblast, ATCC No. CRL-1772, ATCC, Manassas, VA, USA) and RAW264.7 cells (murine monocyte/macrophage, ATCC No. TIB-71) were plated in six-well plates at 2 × 10 5 cells/ml. The C2C12 cells were grown in Dulbecco's modified Eagle media (D-MEM) (Gibco-BRL, Burlington, ON, Canada) containing 10% horse serum (Gibco-BRL) in order to enhance myocyte differentiation and myotube formation. The RAW264.7 cells were grown in D-MEM containing 10% fetal bovine serum (Gibco-BRL). The cells were grown to approximately 60% confluency and then transfected with pCMV-luc (1 or 5 g), pMCK-luc (5 or 10 g) or p⌬MCK-luc (5 or 10 g) using SuperFect transfection reagent following the protocol provided by the manufacturer (Qiagen). Each transfection was performed in duplicate. Forty-eight hours following the transfection, the cells were isolated and luciferase activity was determined using the Luciferase Assay System according to the manufacturer's suggested protocol (Promega, Madison, WI, USA). Protein content was determined by the microassay method using the BioRad Protein Assay Reagent (Hercules, CA, USA). Levels of luciferase activity were expressed as relative light units (RLU)/s/mg protein.
HBsAg expression: C2C12 and RAW264.7 cells were grown in six-well plates as described in the previous section with the exception that sterile coverslips (1 oz micro cover glasses; VWR Scientific, Media, PA, USA) were placed on the bottom of the wells. Cells were allowed to grow to approximately 60% confluency and then transfected with pCMV * -S, pMCK-S and p⌬MCK-S plasmid DNA (10 g) using SuperFect as described above. These cell lines were also transfected with pCMV * backbone vector, that is without the S gene, for use as a negative control. Forty-eight hours following transfection, the coverslips were removed and washed three times by immersion for 5 min in 2 ml of sterile PBS. The coverslips were then air-dried and cells were fixed for 2.5 min with ice cold acetone and washed a further three times with 2 ml of sterile PBS. After this, the cells were blocked for 15 min using 60 l/coverslip of fetal bovine serum to avoid non-specific interactions, and then washed again three times using 2 ml of sterile PBS. The cells were then incubated for 30 min at room temperature (RT) with 60 l/coverslip of the primary antibody (anti-HBs in pooled plasma from BALB/c mice immunized with recombinant HBsAg; each animal had a total IgG titer >150 000). Following this incubation, the cells were washed three times with sterile PBS. The cells were then incubated for 30 min at RT with 60 l/coverslip of secondary antibody sheep anti-mouse Ig-Fluorescein F[ab'] 2 fragment (Boehringer, Mannheim, Germany). The coverslips were washed a final time and mounted on a glass microscope slide (Frosted microscope slides; Fisher Scientific, Pittsburgh, PA, USA) using Permount (Fisher Scientific, Fair Lawn, NJ, USA). The cells were examined by confocal microscopy for HBsAg expression, which was evident as green fluorescence.
In vivo evaluation of gene transfer and immune responses
Direct gene transfer in muscles of mice: All experiments were carried out using female BALB/c mice (Charles River, Montreal, Canada) at 6-10 weeks of age. All experimental groups comprised 6-10 animals. Mice were maintained at the animal care facility at Loeb Health Research Institute. The DNA solutions were administered by i.m. injection into the left tibialis anterior (TA) muscles in a total volume of 50 l as previously described. 27 Evaluation of in vivo expression of luciferase: TA muscles were removed from mice 3 or 6 days after injection of DNA, and luciferase activity was assayed as previously described. 27 Luciferase activity was reported as group means ± s.e.m. in relative light units (RLU)/s/muscle.
Evaluation of humoral responses to HBsAg:
Mice were bled at regular time intervals after injection as described elsewhere 12 and the plasma was recovered and stored at 4°C until assayed. Antibodies (total IgG) specific to HBsAg (anti-HBs) were detected and quantified by endpoint dilution ELISA assay which was performed in triplicate on samples from individual animals.
14 Endpoint titers were defined as the highest plasma dilution that resulted in an absorbance value (OD 450) two times greater than that of non-immune plasma with a cut-off value of 0.05. These were reported as group mean titers ± s.e.m. Seroconversion was defined as titers >100.
In order to investigate the anamnestic humoral immune responses, animals previously injected with HBsAg-expressing DNA were injected i.m. (into the right TA muscle) with 1 g of recombinant HBsAg (Genzyme, San Carlos, CA, USA) in a total volume of 50 l. As a negative control, some naive (ie no previous treatment) animals were injected with HBsAg to determine the characteristics (kinetic and magnitude) of a primary response. As a positive control, mice that had been immunized with pCMV * -S (10 g in 20 l bilaterally into the posterior thigh muscles) at 7 days of age in the presence of maternal anti-HBs were, as adults (once maternal antibody had been lost), injected with HBsAg. We have previously shown this to prime a response in most animals, even though no detectable anti-HBs remains once the maternal antibodies diminish. 28 Evaluation of CTL responses to HBsAg: From all experimental groups, five animals were killed and spleens were removed at 4 weeks after injection and used for CTL assay, which were conducted as previously described. 29 Briefly, splenocytes were restimulated for 5 days using mouse mastocytoma cells expressing HBsAg (p815-S) and CTL activity was measured by 51 Cr release assay.
51
Crlabeled P815-S cells were used as targets. Wild-type P815 cells were used as controls in the 51 Cr release assay. The culture medium used for restimulation was RPMI 1640 supplemented with 10% fetal bovine serum (Gibco/BRL), penicillin-streptomycin solution (final concentration of 1000 U/ml and 1 mg/ml, respectively; Sigma, Irvine, UK), 5 × 10 -5 m ␤-mercaptoethanol (Sigma) and 10 U/ml mouse recombinant IL-2 (Sigma). The results are presented as % specific lysis at an effector:target (E:T) ratio of 50:1, which was representative of relative results obtained at other E:T ratios.
Statistical analysis: Statistical analysis was performed using InStat program (Graph PAD Software, San Diego, CA, USA). The statistical difference between groups was determined by Student's t test (for two groups) or by 1-factor ANOVA followed by Tukey's test (for three or more groups) on raw data or transformed data (log 10 , for heteroscedastic populations).
